TALAZOPARIB TOSYLATE
| Brand name | TALZENNA |
|---|---|
| Active ingredient | TALAZOPARIB TOSYLATE |
| Strength | EQ 0.75MG BASE |
| Dosage form | CAPSULE |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | March 2024 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 8735392 | October 2031 | substance, product |
| 10189837 | October 2031 | substance, product |
| 10780088 | July 2029 | use U-3651 |
| 9820985 | July 2029 | use U-2437 |
| 8012976 | July 2029 | substance, product |
| 8420650 | July 2029 | substance, product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.